Skip to main content
Top
Published in: Journal of Neurology 4/2015

01-04-2015 | Letter to the Editors

Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS

Authors: F. Lauda, T. Fangerau, K. Javaheripour-Otto, E. Pinkhardt, J. Kassubek, H. Tumani

Published in: Journal of Neurology | Issue 4/2015

Login to get access

Excerpt

Dear Sirs, …
Literature
1.
go back to reference Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ et al (2013) PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 80(15):1430–1438PubMedCentralCrossRefPubMed Berger JR, Aksamit AJ, Clifford DB, Davis L, Koralnik IJ, Sejvar JJ et al (2013) PML diagnostic criteria: consensus statement from the AAN neuroinfectious disease section. Neurology 80(15):1430–1438PubMedCentralCrossRefPubMed
2.
go back to reference Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9(4):438–446CrossRefPubMed Clifford DB, De Luca A, Simpson DM, Arendt G, Giovannoni G, Nath A (2010) Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases. Lancet Neurol 9(4):438–446CrossRefPubMed
3.
go back to reference Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C et al (2013) Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84(10):1068–1074PubMedCentralCrossRefPubMed Dahlhaus S, Hoepner R, Chan A, Kleiter I, Adams O, Lukas C et al (2013) Disease course and outcome of 15 monocentrically treated natalizumab-associated progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry 84(10):1068–1074PubMedCentralCrossRefPubMed
4.
go back to reference Linda H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T et al (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361(11):1081–1087CrossRefPubMed Linda H, von Heijne A, Major EO, Ryschkewitsch C, Berg J, Olsson T et al (2009) Progressive multifocal leukoencephalopathy after natalizumab monotherapy. N Engl J Med 361(11):1081–1087CrossRefPubMed
5.
go back to reference Khatri BO, Man S, Giovannoni G, Koo AP, Lee JC, Tucky B et al (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72(5):402–409PubMedCentralCrossRefPubMed Khatri BO, Man S, Giovannoni G, Koo AP, Lee JC, Tucky B et al (2009) Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72(5):402–409PubMedCentralCrossRefPubMed
6.
go back to reference Tan IL, McArthur JC, Clifford DB, Major EO, Nath A (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77(11):1061–1067PubMedCentralCrossRefPubMed Tan IL, McArthur JC, Clifford DB, Major EO, Nath A (2011) Immune reconstitution inflammatory syndrome in natalizumab-associated PML. Neurology 77(11):1061–1067PubMedCentralCrossRefPubMed
7.
go back to reference Thaker AA, Schmitt SE, Pollard JR, Dubroff JG (2014) Natalizumab-induced progressive multifocal leukoencephalopathy. Clin Nucl Med 39(7):e365–e366CrossRefPubMed Thaker AA, Schmitt SE, Pollard JR, Dubroff JG (2014) Natalizumab-induced progressive multifocal leukoencephalopathy. Clin Nucl Med 39(7):e365–e366CrossRefPubMed
8.
go back to reference Kuhle J, Gosert R, Buhler R, Derfuss T, Sutter R, Yaldizli O et al (2011) Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 77(23):2010–2016PubMedCentralCrossRefPubMed Kuhle J, Gosert R, Buhler R, Derfuss T, Sutter R, Yaldizli O et al (2011) Management and outcome of CSF-JC virus PCR-negative PML in a natalizumab-treated patient with MS. Neurology 77(23):2010–2016PubMedCentralCrossRefPubMed
9.
go back to reference Calic Z, Cappelen-Smith C, Hodgkinson SJ, McDougall A, Cuganesan R, Brew BJ (2014) Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. J Clin Neurosci. doi:10.1016/j.jocn.2014.08.016 Calic Z, Cappelen-Smith C, Hodgkinson SJ, McDougall A, Cuganesan R, Brew BJ (2014) Treatment of progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome with intravenous immunoglobulin in a patient with multiple sclerosis treated with fingolimod after discontinuation of natalizumab. J Clin Neurosci. doi:10.​1016/​j.​jocn.​2014.​08.​016
10.
go back to reference Stuve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A et al (2007) Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 64(2):169–176CrossRefPubMed Stuve O, Marra CM, Cravens PD, Singh MP, Hu W, Lovett-Racke A et al (2007) Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: possible interventions. Arch Neurol 64(2):169–176CrossRefPubMed
11.
go back to reference Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O et al (2014) Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry. doi:10.1136/jnnp-2014-307582 PubMed Hoepner R, Ahlbrecht J, Faissner S, Schneider R, Dahlhaus S, Adams O et al (2014) Clinical and paraclinical findings in natalizumab-associated infratentorial progressive multifocal leukoencephalopathy patients. J Neurol Neurosurg Psychiatry. doi:10.​1136/​jnnp-2014-307582 PubMed
12.
go back to reference Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A et al (2013) Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler 19(9):1209–1212CrossRefPubMed Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A et al (2013) Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler 19(9):1209–1212CrossRefPubMed
Metadata
Title
Natalizumab-associated cerebellar PML: a case report on how to slow down IRIS
Authors
F. Lauda
T. Fangerau
K. Javaheripour-Otto
E. Pinkhardt
J. Kassubek
H. Tumani
Publication date
01-04-2015
Publisher
Springer Berlin Heidelberg
Published in
Journal of Neurology / Issue 4/2015
Print ISSN: 0340-5354
Electronic ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7658-y

Other articles of this Issue 4/2015

Journal of Neurology 4/2015 Go to the issue